

EXHIBIT I**AMGEN DISCONTINUES DEVELOPMENT OF
MGDF****FOR IMMEDIATE RELEASE**

THOUSAND OAKS, Calif., September 11, 1998 -- Amgen (NASDAQ:AMGN) today reported that it has discontinued development of its megakaryocyte growth and development factor (PEG-rHuMGDF) due to evidence of neutralizing antibodies in a few patients participating in cancer clinical trials and in additional people in platelet donor clinical trials.

Amgen is a global biotechnology company that discovers, develops, manufactures and markets cost-effective human therapeutics based on advances in cellular and molecular biology.

CONTACT: Amgen, Thousand Oaks
David Kaye, 805/447-6692 (media)
Denise Powell, 805/447-4346 (investors)

###

EDITOR'S NOTE: An electronic version of this news release may be accessed via our web site at www.Amgen.com. Visit the Corporate Center and click on Amgen News. Journalists and media representatives may sign up to receive all news releases electronically at time of announcement by filling out a short form in the Amgen News section of the web site.